AstraZeneca Secures US FDA Approval for ETCAMAH Combination in Advanced Breast Cancer
AstraZeneca Secures US FDA Approval for ETCAMAH Combination in Advanced Breast Cancer BioPharma APAC
Онкология
Рак молочной железы
677 материалов по теме, собраны автоматически из проверенных источников
Онкология
MicroRNA-218 in breast cancer: protective ally or hidden driver?
MicroRNA-218 in breast cancer: protective ally or hidden driver? Bioengineer.org
Онкология
Breast Cancer Treatment Sequencing 2026: Powerful New Insights for Better Outcomes
Breast Cancer Treatment Sequencing 2026: Powerful New Insights for Better Outcomes Oncodaily
Онкология
Predicting pathology response in triple-negative breast cancer using tumor-infiltrating lymphocytes
Predicting pathology response in triple-negative breast cancer using tumor-infiltrating lymphocytes Bioengineer.org
Онкология
FDA approves Guardant360 CDx for ESR1 mutation testing in breast cancer
FDA approves Guardant360 CDx for ESR1 mutation testing in breast cancer MedTech World
Онкология
AstraZeneca breast cancer drug wins US approval after trial cuts progression risk by 56%
AstraZeneca breast cancer drug wins US approval after trial cuts progression risk by 56% Indian Pharma Post
🎗️
Онкология
Affordable, quality breast cancer treatment available in Bangladesh - daily-sun.com
Affordable, quality breast cancer treatment available in Bangladesh daily-sun.com
Онкология
Affordable, quality breast cancer treatment available in Bangladesh
Affordable, quality breast cancer treatment available in Bangladesh Bangladesh Sangbad Sangstha (BSS)
Онкология
Болеют не только женщины: важные вопросы про рак груди у жителей Архангельской области
Болеют не только женщины: важные вопросы про рак груди у жителей Архангельской области 29.ru
Онкология
FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses
FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses Health and Me
Онкология
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer BioSpace
Онкология
Sylvester Earns BCRF Award to Develop AI-Powered Breast Cancer Survivorship Platform
Sylvester Earns BCRF Award to Develop AI-Powered Breast Cancer Survivorship Platform Oncodaily
Онкология
Scientists find breast cancer cells hiding behind protective “shields”
Researchers have mapped breast tumors in striking detail and uncovered hidden pockets of dormant cancer cells that may help explain why cancer can return after treatment. Unlike rapidly dividing cells, these quiet cells can essentially hibernate, allowing them to evade chemotherapy and reactivate later. The team found…
Онкология
A Blood Test, Not a Scan, Now Triggers This Breast Cancer Treatment Switch Under Accelerated Approval
A Blood Test, Not a Scan, Now Triggers This Breast Cancer Treatment Switch Under Accelerated Approval Medical Daily
Онкология
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
FDA Grants Accelerated Approval to a New Breast Cancer Treatment Medical Dialogues